About Multiple Sclerosis Foundation

Home > Learn About Multiple Sclerosis > News > FDA approves Plegridy for MS patients

FDA approves Plegridy for MS patients


Biogen Idec’s Plegridy (TM) received FDA approval as a treatment for relapsing forms of multiple sclerosis. The new drug is administered just under the skin once every two weeks through the use of a single-dose autoinjector, or prefilled syringe. Biogen Idec plans to make Plegridy available in the U.S. in the coming weeks.

The FDA approval of Plegridy is based on the results from a clinical trial which involved more than 1,500 people living with MS. In the study, Plegridy was shown to significantly reduce important clinical and imaging measures, including slowing the progression of disability and decreasing the number of relapses and brain lesions.

Side effects include liver problems; depression or suicidal thoughts; serious allergic reactions; injection site reactions; heart problems, including congestive heart failure; autoimmune diseases; blood problems; seizures; and flu-like symptoms. Patients are advised not to take Plegridy if they are allergic to interferon beta or peginterferon beta-1a, or any of the other ingredients in Plegridy.

For more information on Plegridy, including prescribing information and medication guide, go to PLEGRIDY.com.

  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 


Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved